Skip to Main Content
For healthcare professionals

Phase I study of BI 3923948 with ezabenlimab in advanced, unresectable, and/or metastatic solid tumors (NCT07395258)

 

Phase I open-label, dose escalation trial of VSV-GP oncolytic virus (BI 3923948) monotherapy and in combination with ezabenlimab (PD-1 inhibitor) in patients with advanced, unresectable, and/or metastatic solid tumors (NCT07395258)1

NCT07395258 (1538-0001)
NCT07395258 (1538-0001)

AE, adverse event; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; GP, glycoprotein; IT, intratumoral; MTD, maximum tolerated dose; PD-1, programmed cell death protein-1; RECIST, Response Evaluation Criteria in Solid Tumours; VSV, vesicular stomatitis virus.

References

  1. ClinicalTrials.gov. NCT07395258. https://clinicaltrials.gov/study/NCT07395258 (Accessed: October 2026).